SUTENT is used to treat GIST (gastrointestinal stromal tumor). This is a rare cancer of the stomach, bowel, or esophagus. SUTENT is used when the medicine Gleevec® (imatinib mesylate) did not stop the cancer from growing or when you cannot take Gleevec.
Gleevec is a registered trademark of Novartis AG.
Watch nurse Marilyn Mulay discuss common questions and answers about SUTENT for the treatment of imatinib-resistant or -intolerant GIST.
To watch oncology nurse Marilyn Mulay answer some questions about cancer and SUTENT,
you must have Adobe
® Flash
® installed on your computer.
Please access the SUTENT patient
Medication Guide and
full prescribing information for important safety updates about SUTENT.
 |
In order to view PDF documents, you must have Adobe® Reader®
installed on your computer. If you do not have Adobe Reader, download it from the
Adobe Web site.
|
Note that the Adobe Web site is neither owned nor controlled by Pfizer. Pfizer is
not responsible for the content or services on that site.
Adobe, the Adobe logo, and Reader are registered trademarks of Adobe Systems Incorporated
in the United States and/or other countries.